Related Experiment Video
Updated: Feb 7, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
Amy L MacNeill1, Kristen M Weishaar2, Bernard Séguin3
1Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA. amy.macneill@colostate.edu.
Abstract:
Many oncolytic viruses that are efficacious in murine cancer models are ineffective in humans. The outcomes of oncolytic virus treatment in dogs with spontaneous tumors may better predict human cancer response and improve treatment options for dogs with cancer. The objectives of this study were to evaluate the safety of treatment with myxoma virus lacking the serp2 gene (MYXVΔserp2) and determine its immunogenicity in dogs. To achieve these objectives, dogs with spontaneous soft tissue sarcomas were treated with MYXVΔserp2 intratumorally (n = 5) or post-operatively (n = 5). In dogs treated intratumorally, clinical scores were recorded and tumor biopsies and swabs (from the mouth and virus injection site) were analyzed for viral DNA at multiple time-points. In all dogs, blood, urine, and feces were frequently collected to evaluate organ function, virus distribution, and immune response. No detrimental effects of MYXVΔserp2 treatment were observed in any canine cancer patients. No clinically significant changes in complete blood profiles, serum chemistry analyses, or urinalyses were measured. Viral DNA was isolated from one tumor swab, but viral dissemination was not observed. Anti-MYXV antibodies were occasionally detected. These findings provide needed safety information to advance clinical trials using MYXVΔserp2 to treat patients with cancer.
Insights
Myxoma virus lacking the serp2 gene (MYXVΔserp2) showed a good safety profile in dogs with soft tissue sarcomas. This oncolytic virus is a promising candidate for further clinical trials in cancer patients.
Area of Science:
- Oncolytic virotherapy
- Veterinary oncology
- Immunology
Background:
- Many oncolytic viruses effective in mouse models fail in human trials.
- Canine cancer models offer a more predictive platform for human treatment outcomes.
- Myxoma virus (MYXV) is a potential oncolytic agent.
Purpose of the Study:
- To assess the safety of myxoma virus lacking the serp2 gene (MYXVΔserp2) in dogs with spontaneous tumors.
- To determine the immunogenicity of MYXVΔserp2 in canine patients.
- To provide safety data for advancing MYXVΔserp2 into clinical trials.
Main Methods:
- Dogs with spontaneous soft tissue sarcomas received intratumoral or post-operative MYXVΔserp2 treatment.
- Clinical assessments, tumor biopsies, and swabs were analyzed for viral DNA.
- Blood, urine, and feces were monitored for organ function, virus distribution, and immune response.
Main Results:
- No detrimental effects or significant changes in blood profiles, serum chemistry, or urinalysis were observed.
- Viral DNA was detected in one tumor swab; no systemic viral dissemination occurred.
- Anti-MYXV antibodies were occasionally detected, indicating an immune response.
Conclusions:
- MYXVΔserp2 demonstrates a favorable safety profile in dogs with cancer.
- The study provides essential safety data supporting further clinical investigation of MYXVΔserp2.
- Oncolytic virotherapy with MYXVΔserp2 shows potential for canine and human cancer treatment.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Survey Safety
What are Viruses?
Household Wiring And Electrical Safety
Plant Tissue Culture
Introduction to Virus

